{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import Chroma and instantiate a client. The default Chroma client is ephemeral, meaning it will not save to disk.\n",
    "import chromadb\n",
    "\n",
    "# https://docs.trychroma.com/usage-guide\n",
    "client = chromadb.PersistentClient(path=\"./vector_db\")\n",
    "# Create a new Chroma collection to store the supporting evidence. We don't need to specify an embedding fuction, and the default will be used.\n",
    "collection = client.get_or_create_collection(\"clinical_trials\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We need to have the following:\n",
    "- ids\n",
    "- documents\n",
    "- metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "file_path = \"data/NCT04414150.json\"\n",
    "folder = \"data/ctg-studies.json\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 3226/3226 [01:47<00:00, 29.90it/s]\n"
     ]
    }
   ],
   "source": [
    "from module.helpers import *\n",
    "\n",
    "json_data = load_json_file(file_path)\n",
    "clinical_trial_summary = process_clinical_trial_data(json_data)\n",
    "clinical_trial_summary\n",
    "\n",
    "# Go through all the clinical trials in the folder and add them to the collection\n",
    "import os\n",
    "from tqdm import tqdm\n",
    "\n",
    "for file in tqdm(os.listdir(folder)):\n",
    "    if file.endswith(\".json\"):\n",
    "        json_data = load_json_file(os.path.join(folder, file))\n",
    "        clinical_trial_summary = process_clinical_trial_data(json_data)\n",
    "        summary_to_embed = format_clinical_trial_summary(clinical_trial_summary)\n",
    "        metadata = turn_json_to_valid_metadata(clinical_trial_summary)\n",
    "        collection.add(\n",
    "            ids=[clinical_trial_summary[\"NCT ID\"]],\n",
    "            documents=[summary_to_embed],\n",
    "            metadatas=[metadata],\n",
    "        )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Clinical Trial Summary:\n",
      "\n",
      "NCT ID: NCT04502680\n",
      "Brief Title: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple\n",
      "Negative Breast Cancer Patients\n",
      "Brief Summary: This clinical trial is a multicenter, randomized, open-label, phase-II study to\n",
      "evaluate the efficacy and safety of maintenance treatment with eribulin mesylate\n",
      "following standard adjuvant chemotherapy in triple negative breast cancer\n",
      "patients.\n",
      "Official Title: A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy\n",
      "and Safety of Maintenance Treatment With Eribulin Mesylate Following Standard\n",
      "Adjuvant Chemotherapy in Triple Negative Breast Cancer Patients\n",
      "Conditions:\n",
      "• Triple Negative Breast Cancer\n",
      "\n",
      "Interventions Description:\n",
      "• Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.\n",
      "\n",
      "Eligibility Criteria:\n",
      "Healthy Volunteers: False\n",
      "Sex: FEMALE\n",
      "Minimum Age: 18 Years\n",
      "Standard Ages: ['ADULT', 'OLDER_ADULT']\n",
      "Inclusion Criteria:  * The patient volunteers and signs an informed consent form; * Age ≥18 years\n",
      "old, female; * The patient was diagnosed as triple-negative breast cancer by histopathology (ER\n",
      "negative (IHC ER positive percentage \\<1%), PR negative (IHC PR positive percentage \\<1%), HER2\n",
      "negative (IHC-/+ or IHC++ but FISH/CISH- )), and there is no evidence of metastasis; * Patients\n",
      "underwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary\n",
      "breast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular\n",
      "carcinoma is not considered a positive margin. * For patients who have previously received\n",
      "neoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the\n",
      "postoperative efficacy evaluation did not reach pathological complete remission (non-PCR), that is,\n",
      "the primary breast and/or metastatic regional lymph nodes still have histological evidence of\n",
      "malignant tumors other than carcinoma in situ; * For patients who have not received neoadjuvant\n",
      "therapy for triple-negative breast cancer, ≥1 ipsilateral axillary lymph nodes have pathological\n",
      "tumor involvement after surgery. Or the patient's postoperative lymph nodes are negative, but at\n",
      "least meet one of the following conditions:    1. Primary invasive tumor size\\> 2cm in pathology;\n",
      "2. Ki-67 index of untreated breast tissue\\>30%;   3. The comprehensive score is at least 8 points\n",
      "(Elston and Ellis 1991) according to the improved Bloom-Richardson grading system (also known as the\n",
      "Nottingham scale), which belongs to the 3rd level; * Physical condition ECOG PS: 0-1; * Previously\n",
      "received adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines combined\n",
      "taxanes; * Time window between end of adjuvant chemotherapy and study randomization must be less\n",
      "than 8 weeks. In patients receiving adjuvant radiotherapy, time window allowed between last session\n",
      "and randomisation is 4 weeks; * Laboratory tests meet the following criteria:    1. Bone marrow\n",
      "function: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin\n",
      "(HB)≥90g/L;   2. Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit\n",
      "of normal (ULN) \\*1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN\\*2.5;\n",
      "3. Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min\n",
      "(calculated using the Cockcroft-Gault formula).  Exclusion Criteria:  * Patients with metastatic\n",
      "breast cancer (including contralateral axillary lymph nodes), inflammatory carcinomas; * Previous\n",
      "breast cancer history (except for ipsilateral DCIS that only received local treatment ≥5 years ago),\n",
      "malignant tumors of other histological origins (except for non-melanoma skin cancer or cervical\n",
      "carcinoma in situ) unless the patient's tumor had been completely alleviated and had not received\n",
      "treatment for at least 5 years before the enrollment date; * Major surgery within 4 weeks prior to\n",
      "enrollment, or surgical wounds have not healed; * Embolization and bleeding occurred within 4 weeks\n",
      "before enrollment; * Severe cardiovascular disease, including hypertension (BP≥160/95mmHg)\n",
      "uncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6\n",
      "months, congestive heart failure\\>NYHA II, severe heart rhythm Abnormalities and pericardial\n",
      "effusions; * Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; *\n",
      "Suffering from mental illness, poor compliance; * Researchers believe that it is not suitable for\n",
      "inclusion.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'ids': [['NCT04502680',\n",
       "   'NCT05447702',\n",
       "   'NCT05402722',\n",
       "   'NCT05205200',\n",
       "   'NCT05909332',\n",
       "   'NCT04567420',\n",
       "   'NCT03077776',\n",
       "   'NCT05749588',\n",
       "   'NCT05722795',\n",
       "   'NCT02926196']],\n",
       " 'distances': [[0.5424139499664307,\n",
       "   0.5643917918205261,\n",
       "   0.5773933529853821,\n",
       "   0.5781291127204895,\n",
       "   0.589830756187439,\n",
       "   0.6017122268676758,\n",
       "   0.6144187450408936,\n",
       "   0.6267913579940796,\n",
       "   0.6281962394714355,\n",
       "   0.6422033309936523]],\n",
       " 'metadatas': [[{'Brief Summary': 'This clinical trial is a multicenter, randomized, open-label, phase-II study to evaluate the efficacy and safety of maintenance treatment with eribulin mesylate following standard adjuvant chemotherapy in triple negative breast cancer patients.',\n",
       "    'Brief Title': 'Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients',\n",
       "    'Conditions': 'Triple Negative Breast Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * The patient volunteers and signs an informed consent form; * Age ≥18 years\\nold, female; * The patient was diagnosed as triple-negative breast cancer by histopathology (ER\\nnegative (IHC ER positive percentage \\\\<1%), PR negative (IHC PR positive percentage \\\\<1%), HER2\\nnegative (IHC-/+ or IHC++ but FISH/CISH- )), and there is no evidence of metastasis; * Patients\\nunderwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary\\nbreast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular\\ncarcinoma is not considered a positive margin. * For patients who have previously received\\nneoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the\\npostoperative efficacy evaluation did not reach pathological complete remission (non-PCR), that is,\\nthe primary breast and/or metastatic regional lymph nodes still have histological evidence of\\nmalignant tumors other than carcinoma in situ; * For patients who have not received neoadjuvant\\ntherapy for triple-negative breast cancer, ≥1 ipsilateral axillary lymph nodes have pathological\\ntumor involvement after surgery. Or the patient's postoperative lymph nodes are negative, but at\\nleast meet one of the following conditions:    1. Primary invasive tumor size\\\\> 2cm in pathology;\\n2. Ki-67 index of untreated breast tissue\\\\>30%;   3. The comprehensive score is at least 8 points\\n(Elston and Ellis 1991) according to the improved Bloom-Richardson grading system (also known as the\\nNottingham scale), which belongs to the 3rd level; * Physical condition ECOG PS: 0-1; * Previously\\nreceived adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines combined\\ntaxanes; * Time window between end of adjuvant chemotherapy and study randomization must be less\\nthan 8 weeks. In patients receiving adjuvant radiotherapy, time window allowed between last session\\nand randomisation is 4 weeks; * Laboratory tests meet the following criteria:    1. Bone marrow\\nfunction: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin\\n(HB)≥90g/L;   2. Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit\\nof normal (ULN) \\\\*1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN\\\\*2.5;\\n3. Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min\\n(calculated using the Cockcroft-Gault formula).  Exclusion Criteria:  * Patients with metastatic\\nbreast cancer (including contralateral axillary lymph nodes), inflammatory carcinomas; * Previous\\nbreast cancer history (except for ipsilateral DCIS that only received local treatment ≥5 years ago),\\nmalignant tumors of other histological origins (except for non-melanoma skin cancer or cervical\\ncarcinoma in situ) unless the patient's tumor had been completely alleviated and had not received\\ntreatment for at least 5 years before the enrollment date; * Major surgery within 4 weeks prior to\\nenrollment, or surgical wounds have not healed; * Embolization and bleeding occurred within 4 weeks\\nbefore enrollment; * Severe cardiovascular disease, including hypertension (BP≥160/95mmHg)\\nuncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6\\nmonths, congestive heart failure\\\\>NYHA II, severe heart rhythm Abnormalities and pericardial\\neffusions; * Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; *\\nSuffering from mental illness, poor compliance; * Researchers believe that it is not suitable for\\ninclusion.\",\n",
       "    'Interventions Description': 'Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.',\n",
       "    'NCT ID': 'NCT04502680',\n",
       "    'Official Title': 'A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Maintenance Treatment With Eribulin Mesylate Following Standard Adjuvant Chemotherapy in Triple Negative Breast Cancer Patients'},\n",
       "   {'Brief Summary': 'The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).',\n",
       "    'Brief Title': 'Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)',\n",
       "    'Conditions': 'Triple Negative Breast Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 75 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * Newly diagnosed breast cancer. * 18-75 Years, female. * Early or locally\\nadvanced, histologically documented TNBC (absence of HER2, ER, and PR expression). * Tumor stage:\\nII-III. * ECOG Performance Status of 0-1. * life expectancy is not less than 3 months. * at least\\none measurable lesion according to RECIST 1.1. * Adequate hematologic and organ function. * Must be\\nwilling to use an adequate method of contraception for the course of the study.  Exclusion Criteria:\\n* Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer. * Inflammatory breast cancer. * Has\\nreceived prior any anti-tumor therapy within the past 12 months prior to signing informed consent,\\nincluding chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TAE. *\\nHas received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed\\ndeath-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory\\nT-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \\\\[CTLA-4\\\\], and/or anti-VEGFR\\nagent. * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for\\nadequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Major\\nsurgical procedure within 4 weeks prior to initiation of study treatment. * Has a history of\\nautoimmune disease. * Has a history of hypertension that not well controlled by antihypertensive\\ntreatment * Has a history of myocardial infarction, severe/unstable angina pectoris, NYHA Class 2 or\\nabove cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, or\\nsymptomatic congestive heart failure within the last 6 months. * Has a history of (non-infectious)\\npneumonitis, interstitial lung disease or uncontrollable systematicness diseases. * Administration\\nof a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation\\nof need for such a vaccine during the study. * Has a known history of Human Immunodeficiency Virus\\n(HIV). * Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis. * Severe infections\\nwithin 4 weeks prior to initiation of study treatment, including but not limited to hospitalization\\nfor complications of infection, bacteremia, or severe pneumonia. * Has active infection (CTCAE≥2)\\nneeded the treatment of antibiotic within 2 weeks prior to initiation of study treatment. * Has\\nevidence of active tuberculosis within 1 year prior to initiation of study treatment. * Prior\\nallogeneic stem cell or solid organ transplantation. * Peripheral neuropathy grade ≥2. * Has\\nclinically significant intestinal obstruction. * Arterial/venous thrombosis events that occurred\\nwithin 3 months before enrollment, such as cerebrovascular accidents, deep vein thrombosis, or\\npulmonary embolism. * Has hemoptysis symptoms within 2 months before enrollment and the maximum\\ndaily hemoptysis ≥ 2.5 ml. * Clinically significant bleeding symptoms or clear bleeding tendency\\noccurred within 3 months before enrollment. * Has known genetic or acquired bleeding or thrombotic\\ntendency. * Abnormal coagulation (INR\\\\>1.5 or APTT\\\\>1.5 x ULN) with bleeding tendency, receiving\\nthrombolysis or anticoagulation therapy, or requiring long-term antiplatelet therapy. * Has a known\\nhypersensitivity to the components of the study treatment or other hypersensitivity reactions to\\nchimeric or humanized antibodies or fusion proteins. * Female patients during pregnancy and\\nlactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are\\nunwilling to take effective contraceptive measures throughout the trial. * History of neurological\\nor psychiatric disorders, including epilepsy or dementia. * Any other situation evaluated by\\nresearchers.\",\n",
       "    'Interventions Description': 'Intravenous (IV) infusion, po., IV infusion., IV infusion., IV infusion.',\n",
       "    'NCT ID': 'NCT05447702',\n",
       "    'Official Title': 'A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)'},\n",
       "   {'Brief Summary': 'To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.',\n",
       "    'Brief Title': 'Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer',\n",
       "    'Conditions': 'TNBC - Triple-Negative Breast Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 75 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. The patients sign the written informed consent. 2. Women aged 18-75. 3. The\\npathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［ER-\\nnegative(IHC\\\\<1%), PR-negative(IHC\\\\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］. Patients\\nwith at least one measuring lesion that was conformed to RECIST v1.1 standard. 4. PD-1/PD-L1positive\\nor TMB≥5. 5. Prior therapy (adjuvant/neoadjuvant/advanced) must have included an anthracycline\\nand/or a taxane in any combination or order and either in the early or metastatic disease setting\\nunless contraindicated for a given patient. 6. Eastern Cooperative Oncology Group (ECOG) performance\\nstatus of ≤ 1. 7. The results of patient's blood tests are as follows:     • Hb≥90g/L; •\\nPlt≥100\\\\^9/L; • Serum albumin ≥3g/dL;• Neutrophils≥1.5\\\\^9/L; TSH≤ normal upper limit (ULN);• ALT and\\nAST ≤1.5 ULN (liver metastases ≤3 ULN); • TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome\\nor liver metastasis subjects);• ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);• AKP≤ 2.5 ULN; •\\nRenal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or\\ncreatinine clearance ≥60mL/min 8. Female subjects of childbearing potential must have a negative\\nserum pregnancy test within 7 days before the first dose and must be willing to use very efficient\\nbarrier methods of contraception for the course of the study through 6 months after the last dose of\\nstudy treatment.  Exclusion Criteria:  1. The subjects had a central nervous system metastases with\\nclinical symptoms. 2. Subjects with treatment history of PD-1 / PD-L1 inhibitors; 3. Peripheral\\nneuropathy ≥ grade 2; Cardiac dysfunction, hyperthyroidism or hypothyroidism, type 1 diabetes,\\nactive hepatitis and tuberculosis; Autoimmune diseases requiring systemic treatment, and a history\\nof pneumonia (requiring corticosteroid treatment) or interstitial lung disease. 4. Pregnant or\\nlactating women. 5. Other clinical trials of drugs were used in the first four weeks before the\\nfirst dose. 6. The subjects had any history of autoimmune disease or any use of systemic\\nglucocorticoid or immunosuppressive medications. 7. Hereditary or acquired bleeding and thrombotic\\ntendencies (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.). 8.\\nCongenital or acquired immune deficiency (such as HIV infection); 9. Receive live vaccine within 4\\nweeks before or during the study period; 10. Patients who are allergic to or contraindicated to the\\nexperimental drugs. 11. Other malignant tumors in the past, except cervical cancer and non melanoma\\nskin cancer, which have survived for 5 years without disease. 12. Subjects with any other diseases\\nthat are unfit for the treatment.\",\n",
       "    'Interventions Description': 'Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle, Sintilimab Injection，Intravenous infusion，200mg，3-week cycle',\n",
       "    'NCT ID': 'NCT05402722',\n",
       "    'Official Title': 'A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer'},\n",
       "   {'Brief Summary': 'This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.',\n",
       "    'Brief Title': 'Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)',\n",
       "    'Conditions': 'Breast Cancer, Metastatic Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 75 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * Females ≥18 years and ≤ 75 years old; * Histologically confirmed HR + / HER2-\\ninvasive breast cancer (specific definition: immunohistochemical detection of ER\\\\> 10% tumor cell\\npositive is defined as ER positive, PR\\\\> 10% tumor cell positive is defined as PR positive, ER and /\\nor PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH\\ndetection, no amplification, defined as HER2 negative); * Subtype of similarity network fusion-2\\n(SNF-2) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan\\nUniversity Affiliated Cancer Hospital * Locally advanced breast cancer (incapable of radical local\\ntreatment) or recurrent metastatic breast cancer; * Measurable disease according to Response\\nEvaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic +\\nosteoblastic) bone lesions in the absence of measurable lesions; * Has adequate bone marrow\\nfunction: absolute neutrophil count \\\\> 1.5x10ˆ9 /L; platelet count \\\\> 75x10ˆ9 /L, hemoglobin \\\\>\\n9g/dL; * Patients had received no previous chemotherapy or targeted therapy for metastatic disease *\\nHas adequate liver function and kidney function: serum creatinine * ECOG score ≤ 2 and life\\nexpectancy ≥ 3 months; * Participants voluntarily joined the study, has signed informed consent\\nbefore any trial related activities are conducted, has good compliance and has agreed to follow-up.\\nExclusion Criteria:  * Treatment with chemotherapy, radiotherapy, immunotherapy or surgery\\n(outpatient clinic surgery excluded) for metastatic disease    * Symptomatic, untreated, or actively\\nprogressing CNS metastases(glucocorticoids or mannitol needed to control symptoms);   * Significant\\ncardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or\\nventricular arrhythmia in the last 6 months);   * is pregnant or breast feeding;   * Malignant\\ntumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in\\nsitu).   * History of autoimmune disease   * Positive test for human immunodeficiency virus   *\\nActive hepatitis B or hepatitis C   * Uncontrolled pleural effusion and ascites   * Thyroid\\ndysfunction.\",\n",
       "    'Interventions Description': 'PD-L1 antibody, CDK4/6 inhibitor, Albumin bound paclitaxel, Fulvestrant, aromatase inhibitor',\n",
       "    'NCT ID': 'NCT05205200',\n",
       "    'Official Title': 'Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer'},\n",
       "   {'Brief Summary': 'This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.',\n",
       "    'Brief Title': 'Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients.',\n",
       "    'Conditions': 'Breast Cancer, Triple Negative Breast Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 70 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * Women aged 18-70 years old; * Eastern Oncology Collaborative Group (ECOG)\\nphysical status score: 0 or 1; * Histological results recorded as TNBC (negative HER2, ER, and PgR\\nstatus) and BLIS subtype according to the classification of FUSCC; * Have stage IIA-IIIIC triple-\\nnegative breast cancer with non-metastatic surgically treated: pT1-3N1-3M0; * Adequate hematological\\nand end-organ function as defined by the following laboratory test results, which need to be\\ncompleted within 28 days prior to the first study treatment: absolute neutrophil count (ANC) ≥ 1500\\ncells/μL (no G-CSF support therapy within 2 weeks prior to day 1 of course 1); Platelet count ≥\\n75×109/L (no platelet transfusion within 2 weeks before day 1 of course 1); hemoglobin ≥ 9.0 g/dL\\n(no RBC transfusion within 2 weeks before day 1 of course 1); AST, ALT, and alkaline phosphatase ≤ 3\\n× upper limit of normal (ULN) serum total bilirubin ≤ 1.0 × ULN; serum creatinine ≤ 1ULN and with an\\nendogenous creatinine clearance rate of \\\\>50 ml/min (Cockcroft-Gault formula); * The surgical\\nincision had fully healed prior to the commencement of the study; * Female participants of\\nreproductive potential are required to use a medically accepted form of contraception during the\\ncourse of the study treatment and for at least three months following the last administration of the\\ninvestigational drug; * Sign the Informed Consent Form (ICF). The patient is judged by the\\ninvestigator to have the ability to comply with the provisions of the protocol.  Exclusion Criteria:\\n* Has received neoadjuvant therapy (including chemotherapy, targeted therapy, and radiotherapy) *\\nHas bilateral breast cancer; * Has a previous history of additional malignancy, with the exception\\nof adequately treated basal cell carcinoma and cervical carcinoma in situ. * Has metastatic (Stage\\n4) breast cancer; * Has any \\\\>T4 lesion (UICC1987) (with skin involvement, mass adhesion and\\nfixation, and inflammatory breast cancer); * Has severe organ dysfunction (cardiopulmonary liver and\\nkidney) insufficiency, left ventricular ejection fraction (LVEF) \\\\< 50% (a cardiac ultrasound);\\nsevere cardio cerebral vascular disease within the 6 months previous to randomization (such as\\nunstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\\\\>150/90mmgh,\\nmyocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control;\\npatients with severe hypertension; * Is pregnant, breastfeeding women, or women of childbearing age\\nwho cannot practice effective contraceptives; * Patients participating in other clinical trials at\\nthe same time; * Has known allergy to taxane and excipients. * Has severe or uncontrolled infection;\\n* Has a history of psychotropic substance abuse and was unable to abandon drug habits or those with\\na history of mental disorders; * the researchers judged patients to be unsuitable for the study.\",\n",
       "    'Interventions Description': 'BP102 (anti VEGFR), ddEC-P',\n",
       "    'NCT ID': 'NCT05909332',\n",
       "    'Official Title': 'A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant Therapy for Patients With Triple-Negative Breast Cancer, Basal-like Immunosuppressed Subtype.'},\n",
       "   {'Brief Summary': 'A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)',\n",
       "    'Brief Title': 'DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer',\n",
       "    'Conditions': 'Breast Cancer',\n",
       "    'Eligibility': 'Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nStandard Ages: [\\'CHILD\\', \\'ADULT\\', \\'OLDER_ADULT\\']\\nInclusion Criteria:  - 4.1.1. Stage II or III, HER2 negative, ER positive invasive breast cancer in\\nmale or female patients. For this study, ER positivity is defined as equal to or greater than 10% ER\\npositivity by immunohistochemistry, regardless of progesterone receptor (PR) status. Patients with\\nPR positive but ER negative cancer are not eligible. HER2 negative status is defined as per the\\nASCO/CAP 2018 practice guidelines.  (i) if patients have synchronous bilateral ER+ breast cancer\\ntissue from both sites should be submitted to Natera to perform ctDNA testing.  (ii) patients with\\nmultifocal/multicentric tumors are eligible and the largest focus of cancer should be submitted for\\ntesting. All tumors must meet pathological criteria for HER2-and ER+ status.  (iii) For. patients\\nwho received neoadjuvant therapy and have discordant ER and HER2 results between the diagnostic\\nbiopsy (pre-treatment) and surgical pathology (post neoadjuvant therapy), the ER+ and HER2- status\\nof the post-treatment specimen determine eligibility.  4.1.2. Currently taking an aromatase\\ninhibitor, or tamoxifen, as adjuvant endocrine therapy and have completed at least 6 months (i.e. 24\\nweeks), but no more than 7 years with 3 more years planned, of endocrine therapy. Patients may\\nregister for the screening phase of the study within the first 6 months of adjuvant endocrine\\ntherapy but the first ctDNA testing must occur at, or after, 6 months of endocrine therapy.  (i)\\nAdjuvant bisphosphonate therapy is allowed. (ii) LHRH analogues are required for premenopausal\\npatients randomized to receive fulvestrant.  4.1.3. Clinical and pathological high risk for\\nrecurrence defined as any one of the following: (i) At least a 15% predicted risk of death within 10\\nyears using ePREDICT V2.1 (https://breast.predict.nhs.uk/tool), or (ii) At least 15% or greater risk\\nof distant metastasis within 10 years using RSPC,\\n(https://tools.genomichealth.com/Tools/RSPCTool.aspx), or (iii) At least 15% or greater risk of\\ndistant metastasis within 10 years CTS5 (https://www.cts5-calculator.com) for patients who have\\ncompleted a minimum of 4 years of adjuvant endocrine therapy, or (iv) Tumor size \\\\> 5 cm, regardless\\nof lymph node status, or (v) 1-3 involved axillary lymph nodes and at least one of the following;  *\\nTumor size \\\\> 3 cm, * High histological grade (e.g. grade 3). * High genomic risk defined as\\nOncotype Dx Recurrence Score \\\\>26, EndoPredict score \\\\>4, Prosigna risk of recurrence score ≥ 60, or\\nMammaprint high risk.  (vi) Patients who have received pre-operative (neoadjuvant) chemotherapy must\\nhave either:  * greater than or equal to 3 cm invasive residual cancer regardless of nodal status\\nAND grade 3 disease or RS\\\\>26/MammPrint High/Prosigna high/Endopredict high status, or * greater\\nthan or equal to 1 cm invasive residual cancer (ypT1c) and at least 1 positive lymph node (ypN+) AND\\ngrade 3 disease, or RS\\\\>26, or MammPrint High, or Endopredict high or Prosigna high status.  4.1.4.\\nPatients must have FFPE tissue from the primary tumor available for submission to Natera to perform\\nctDNA assay (see Appendix B for tissue submission instructions).  4.1.5. Signed and dated informed\\nconsent, including willingness to be randomized to standard of care versus fulvestrant +\\npalbociclib.  4.2 Inclusion and exclusion criteria for treatment randomization  Inclusion criteria\\nfor randomization  4.2.1. ctDNA positivity by the Signatera assay, defined as 2 of the 16 cancer\\nspecific markers positive in plasma.  4.2.2. Patients with positive Signatera results obtained in\\nthe context of commercial testing, outside of the screening phase of this trial, are also eligible\\nfor randomization if they meet other eligibility criteria.  4.2.3. No evidence of metastatic disease\\non CT scan of the chest, abdomen and pelvis.  * If imaging, after review with a radiologist, is low\\nprobability for metastatic disease, patients may proceed to randomization. * Patients with\\nsuspicious but inconclusive imaging results should undergo a diagnostic biopsy, if biopsy is\\nnegative patients are eligible for randomization. * Patients with positive imaging that is\\nconclusive of metastatic disease, or with biopsy proven metastatic disease, are not eligible for\\nrandomization.  4.2.4. Pre-menopausal women and male patients must be willing to use an adequate\\nmethod of contraception for the duration of trial treatment and for 4 additional weeks after\\ncompletion of treatment in the control arm, and for 2 years after the last dose of fulvestrant, if\\nrandomized into the experimental arm.  Post-menopausal status is defined as:  * Documented bilateral\\noophorectomy. * Age ≥ 60 years. * Age \\\\< 60 years and amenorrhoeic for ≥ 12 consecutive months and\\nFSH and estradiol levels in the post-menopausal range according to the institutional reference range\\nfor post-menopausal.  Adequate contraception is defined as ONE highly effective form (i.e.\\nabstinence, surgical sterilization through bilateral tubal ligation, vasectomy), or TWO effective\\nforms (e.g. non-hormonal IUD and condom / occlusive cap with spermicidal foam / gel / film / cream /\\nsuppository).  - Abstinence is to be interpreted as \"true abstinence\" for heterosexual intercourse\\nand therefore, \"periodic abstinence\" (e.g. calendar, symptothermal, post-ovulation methods) and\\nwithdrawal (coitus interruptus) are not considered highly effective.  Exclusion Criteria  4.1.5.\\nPrior or current treatment with fulvestrant, or current treatment with a CDK4/6 inhibitor, or\\ntreatment in the prior 12 months, or participants in the PENELOPE and PALLAS clinical trials.\\n4.1.6. Patients cannot start participation in another therapeutic clinical trial for breast cancer\\nafter enrollment in this trial.  4.1.7. Patients with current or past invasive cancer, other than\\nbreast cancer are not eligible, except:  * Adequately treated basal or squamous cell carcinoma of\\nthe skin are eligible. * Cancer survivors of previously diagnosed invasive cancer, who were treated\\nwith a curative intent, have no evidence of disease recurrence for 5 years or more, and are\\nconsidered low risk for future recurrence by the treating physician are also eligible.  4.1.8.\\nPatients with a second HER2 positive or triple negative synchronous breast cancer are not eligible.\\nExclusion criteria for randomization  4.2.5. Patients with known contraindications to receive\\nfulvestrant and palbociclib or those who are unable to tolerate these drugs are not eligible.  *\\nAbsolute neutrophil count less than \\\\<1000/mm3;  4.2.6. Any concurrent severe and uncontrolled\\nmedical condition that would, in the Investigator\\' opinion cause unacceptable safety risks or\\ncompromise compliance with the protocol including but not limited to:  * Impairment of\\ngastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral\\nmedication (e.g. Crohn\\'s disease, ulcerative diseases, uncontrolled chronic nausea, vomiting,\\ndiarrhea, malabsorption syndrome, or small bowel resection). * History of pneumonitis, interstitial\\nlung disease or pulmonary fibrosis. * Known history of Human Immunodeficiency Virus (HIV) (testing\\nis not mandatory). * Known active Hepatitis B or Hepatitis C (testing is not mandatory). * Females\\nwho are pregnant or breastfeeding. * History of bleeding diathesis (i.e. disseminated intravascular\\ncoagulation, clotting factor deficiency) that preclude the IM injections of fulvestrant or LHRH\\nagonist as applicable.  4.2.7 Patients taking any CYPC3A4 strong inducers and inhibitors, that\\ncannot be changed.',\n",
       "    'Interventions Description': '4 week cycles, 4 week cycles, Standard of Care',\n",
       "    'NCT ID': 'NCT04567420',\n",
       "    'Official Title': 'A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer'},\n",
       "   {'Brief Summary': 'A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative breast cancer (TNBC) who are eligible for neoadjuvant chemotherapy.',\n",
       "    'Brief Title': 'Tracking Triple-negative Breast Cancer Evolution Through Therapy',\n",
       "    'Conditions': 'Triple-Negative Breast Neoplasm',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. Age 18-years or older 2. Patients with histological confirmation of invasive\\nbreast cancer with known receptor status suitable for neoadjuvant chemotherapy as assessed by the\\nlocal investigator 3. Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by\\n≤1% of positive staining on immunohistochemistry 4. Human epidermal growth factor receptor 2\\n(HER2)-negative as defined by American Society of Clinical Oncology / College of American\\nPathologists guidelines 5. T1c-4 tumours (including inflammatory cancers), with any nodal status non\\ncandidate for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided\\nthat all sites are HER2-negative and at least one site is ER- and PR-negative. 6. Provision of\\nsigned and dated, written informed consent prior to any study specific procedures, sampling and\\nanalyses 7. Patient with social insurance coverage  Exclusion Criteria:  1. Confirmed metastatic\\ndisease at initial presentation 2. Any contraindication to the biopsy procedure 3. Previous or\\ncurrent malignancies of other origin within the last 5 years, with the exception of in situ\\ncarcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin 4.\\nAny condition which in the Investigator's opinion makes it undesirable for the subject to\\nparticipate in the trial or which would jeopardize compliance with the protocol 5. Individuals\\ndeprived of liberty or placed under the authority of a tutor\",\n",
       "    'Interventions Description': 'Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy, \\\\[Optional\\\\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy, Biopsy of metastatic site to be performed at the time of relapse',\n",
       "    'NCT ID': 'NCT03077776',\n",
       "    'Official Title': 'Tracking Triple-negative Breast Cancer Evolution Through Therapy'},\n",
       "   {'Brief Summary': 'This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.',\n",
       "    'Brief Title': 'FUSCC Refractory TNBC Platform Study (FUTURE2.0)',\n",
       "    'Conditions': 'Triple-negative Breast Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. Female aged ≥18 years; 2. TNBC invasive breast cancer confirmed by histology\\n(specific definition: ER \\\\<1% positive tumor cells by immunohistochemistry is defined as ER\\nnegative, PR \\\\<1% positive tumor cells is defined as PR negative, HER2 0-1+ or HER2 ++ but negative\\nby FISH without amplification was defined as HER2 negative); Locally advanced breast cancer (unable\\nto undergo radical local treatment) or recurrent metastatic breast cancer; 3. Progression after at\\nleast one prior therapeutic regimens for advanced/metastatic TNBC 4. At least one measurable lesion\\naccording to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has\\nnot received radiotherapy); 5. The functions of the main organs are basically normal and meet the\\nfollowing conditions:     i. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood\\ntransfusion within 14 days); The ANC acuity 1.5 x 109 / L; PLT acuity 75 x 109 / L;     ii.\\nBiochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value);\\nALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN,\\nendogenous creatinine clearance \\\\> 50 ml/min (Cockcroft-Gault formula); 6. They have not received\\nradiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study,\\nand have recovered from the acute toxicity of previous treatment (if surgery was performed, the\\nwound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity; 7. ECOG\\nscore ≤1, and life expectancy ≥3 months; 8. Fertile female subjects were required to use a medically\\napproved contraceptive method during the study treatment period and for at least 3 months after the\\nlast use of the study drug; 9. Subjects volunteered to join the study, signed informed consent, had\\ngood compliance, and cooperated with follow-up.  Exclusion Criteria:  1. Radiotherapy (except for\\npalliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment,\\nexcept bisphosphonate (which can be used for bone metastasis); 2. Uncontrolled central nervous\\nsystem metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or\\nmannitol); 3. A history of clinically important or uncontrolled heart disease, including congestive\\nheart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6\\nmonths; 4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The\\nexception to this is hair loss or something the researchers don't think should be ruled out. Such\\ncases should be clearly documented in the investigator's notes; 5. Underwent major surgery (except\\nminor outpatient procedures, such as placement of vascular access) within 3 weeks of the first\\ncourse of trial treatment; 6. Pregnant or lactating patients; 7. Malignancy (except basal cell\\ncarcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5\\nyears.\",\n",
       "    'Interventions Description': 'A1: an anti-HER2 antibody-drug conjugate (ADC), A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)\\n\\nCamrelizumab: an anti-programmed death-1 (PD-1) antibody, B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC, B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC\\n\\nCamrelizumab: an anti-programmed death-1 (PD-1) antibody, C1: an anti-HER2 antibody-drug conjugate (ADC), C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)\\n\\nBP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab), D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC, D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC\\n\\nBP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab), E1: an anti-HER2 antibody-drug conjugate (ADC), F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC, G1: an anti-HER2 antibody-drug conjugate (ADC), H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC',\n",
       "    'NCT ID': 'NCT05749588',\n",
       "    'Official Title': 'Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）'},\n",
       "   {'Brief Summary': 'This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option.\\n\\nThe primary aim is to determine the proportion of patients that converts to estrogen receptor (ER) positive breast cancer in the removed breast cancer tissue at surgery.',\n",
       "    'Brief Title': 'Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)',\n",
       "    'Conditions': 'Breast Cancer, Triple Negative Breast Cancer',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. Histological confirmed invasive primary triple negative breast cancer≥15 mm)\\nwith any node status. 2. Age ≥18 years     Triple Negative subtype is defined below:    1. Hormone\\nreceptor status: the invasive tumour shall be ER- and progesterone receptor (PR) -negative\\n\\\\[staining present in \\\\<10% by immunohistochemistry (IHC)\\\\].    2. HER2 status: the invasive tumour\\nshall be Human Epidermal growth factor Receptor (HER) 2-negative by the American Society of Clinical\\nOncology (ASCO) / College of American Pathologists (CAP) guidelines 3. No previous systemic\\ntreatment for TNBC 4. No concurrent anti-cancer treatment. Treatment with Bisphosphonates may\\ncontinue. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 6. Normal organ\\nfunction as defined below:     1. absolute white blood cell count ≥1.5 x 109/L    2. platelets ≥100\\nx 109/L    3. haemoglobin ≥90g/dL    4. total bilirubin ≤1.5 x institutional upper normal limit\\n(UNL)/dL (≤ 3 x UNL for patients with Gilbert´s syndrome)    5. ASAT, ALAT, GGT and alkaline\\nphosphatase levels \\\\< 1.5 × institutional UNL.    6. albumin \\\\>2.5mg/dL    7. Creatinine \\\\< 110\\nμmol/L    8. T3, T4 and TSH (only patients with previous thyroid dysfunction) 7. Patients of\\nchildbearing potential must have a negative serum or urine pregnancy test within 8 days prior to\\nstart of imatinib treatment..     Female patients of childbearing potential must agree to\\nusecontraceptive methods with a failure rate below 1% per year during the study treatment and at\\nleast 90 days after the last dose of imatinib. 8. Patients must be able to take (swallow) an oral\\nmedication. 9. Patients must be capable to understand and comply with the protocol and has signed\\nthe informed consent.  Exclusion Criteria:  1. Patients suitable for neoadjuvant treatment. 2.\\nConcomitant treatment for breast cancer within 14 days before registration. 3. Unable to adhere to\\nthe study procedures. 4. Evidence of any other medical conditions (such as psychiatric illness,\\ninfectious diseases, neurological conditions, physical examination or laboratory findings) that may\\ninterfere with the planned treatment or affect patient compliance. 5. Pregnancy and breast-feeding.\\n6. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).\\n7. Known human immunodeficiency virus (HIV) positivity. 8. Known active Hepatitis B or Hepatitis C\",\n",
       "    'Interventions Description': 'One tablet daily 10 days before surgery.',\n",
       "    'NCT ID': 'NCT05722795',\n",
       "    'Official Title': 'Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer'},\n",
       "   {'Brief Summary': 'Phase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients. The overall protocol-defined patient population will include the following two strata of patients:\\n\\n* Stratum A - Patients who have completed treatment with curative intent including surgery of the primary tumor followed by adjuvant chemotherapy .\\n* Stratum B - Patients who have completed treatment with curative intent including neoadjuvant chemotherapy followed by surgery of the primary tumor and (if indicated) further adjuvant chemotherapy.',\n",
       "    'Brief Title': 'Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab',\n",
       "    'Conditions': 'Triple Negative Breast Neoplasms',\n",
       "    'Eligibility': \"Eligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria Stratum A (Adjuvant patients) \\\\& B (Post-neoadjuvant patients)  1. Male or female\\nsubjects aged \\\\> 18 years 2. Signed written informed consent before any trial-related procedure is\\nundertaken that is not part of the standard patient management 3. Eastern Cooperative Oncology Group\\n(ECOG) performance status 0 or 1 4. Patients must have completed treatment with curative intent\\nincluding: surgery and adjuvant chemotherapy. 5. Patients must have completed adjuvant chemotherapy\\nincluding at least 3 courses of an anthracycline agent and 3 courses of a taxane agent. Patients who\\nreceived dose-dense regimens and those who received carboplatin as part of the adjuvant treatment\\nare eligible. 6. No more than 10 weeks may elapse between the completion of last adjuvant treatment\\n(adjuvant chemotherapy or surgery) and randomization.  8. Normal organ and marrow function  1. White\\nblood count (WBC) greater than or equal to 2.5 x109/L 2. Absolute neutrophil count (ANC) greater\\nthan or equal to 1.5 x109/L 3. Absolute lymphocyte count greater or equal to 0.5 x109/L 4. Platelet\\ncount greater than or equal to 100 x109/L 5. Hemoglobin greater than or equal to 9 g/dL 6. Serum\\ncreatinine less or equal to 1.5 x the upper limit of laboratory normal range (ULN) 7. Adequate\\nhepatic function defined by a total bilirubin level less or equal to 1.5 x ULN range and AST and ALT\\nlevels less or equal than 2.5 x ULN for all subjects. For patients with known Gilbert's syndrome,\\ntotal bilirubin levels less or equal than 2 x ULN range (with direct bilirubin less than ULN) will\\nbe accepted.     9. Highly effective contraception (i.e. methods with a failure rate of less than 1\\n% per year) for both male and female subjects if the risk of conception exists (Note: The effects of\\nthe trial treatment on the developing human fetus are unknown; thus, women of childbearing potential\\nand men must agree to use highly effective contraception, defined in Appendix A or as stipulated in\\nnational or local guidelines. Highly effective contraception must be used 28 days prior to first\\ntrial treatment administration, for the duration of trial treatment, and at least for 60 days after\\nstopping trial treatment. Should a woman become pregnant or suspect she is pregnant while she or her\\npartner is participating in this trial, the treating physician should be informed immediately).\\n10. Ability to understand and willingness to sign a written informed consent.  Inclusion Criteria\\nStratum A (Adjuvant patients)  1. Non-metastatic, histologically confirmed primary invasive breast\\ncarcinoma 2. Triple negative breast cancer: hormone receptor negative (ER \\\\< 10% and PgR \\\\< 10%) and\\nHER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory. In case\\nof discordance between pre-operative core-biopsy and the surgical sample, the receptor assessment\\nperformed on the surgical sample has to be considered for inclusion criteria evaluation. 3.\\nAvailability of a formalin-fixed, paraffin-embedded block containing tumor tissue or at least 7\\nunstained tumor slides. 4. Adequately excised: patients must have undergone either breast-conserving\\nsurgery or mastectomy/nipple- or skin-sparing mastectomy. The margins of the resected specimen\\nshould be free of invasive tumor and ductal carcinoma in situ (no ink on tumor). In the case of\\nbreast-conserving surgery patients with margins positive for lobular carcinoma in situ (LCIS) are\\neligible without additional resection. For patients who undergo mastectomy, patients with a\\nmicroscopic positive deep margin are eligible, provided they will receive radiotherapy on chest\\nwall. 5. Patients must have had axillary lymph node dissection for evaluation of pathologic nodal\\nstatus. Only patients in one of the following stage categories will be eligible:     * if 4 or more\\nmetastatic lymph nodes, any pT    * if 1 to 3 metastatic lymph nodes, pT \\\\>2 cm    * if no\\nmetastatic lymph nodes, pT \\\\>5 cm  Inclusion criteria:  Stratum B (Post-neoadjuvant patients)  1.\\nNon-metastatic histologically confirmed invasive breast carcinoma. 2. Triple negative breast cancer:\\nhormone receptor negative (ER \\\\< 10% and PgR \\\\< 10%) and HER2 negative (IHC 0/1+ or ISH non-\\namplified), as defined by the local pathology laboratory. In case of discordance between the pre-\\ntreatment diagnostic core-biopsy and the surgical sample, the receptor assessment performed on the\\nsurgical sample has to be considered for inclusion criteria evaluation. 3. Adequately excised:\\npatients should have undergone adequate tumor excision after preoperative chemotherapy, which means\\nsurgical removal of all clinically evident disease in the breast and lymph nodes.     1. Breast\\nsurgery: patients must have undergone either breast-conserving surgery or mastectomy/nipple- or\\nskin-sparing mastectomy. The margins of the resected specimen should be free of invasive tumor and\\nductal carcinoma in situ (no ink on tumor). In the case of breast-conserving surgery patients with\\nmargins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection. For\\npatients who undergo mastectomy, patients with a microscopic positive deep margin are eligible,\\nprovided they will receive radiotherapy on chest wall.    2. Lymph node surgery:     i. Axillary\\ndissection without sentinel node evaluation is permitted after preoperative therapy.     ii. In case\\nof positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed\\nprior to preoperative therapy, additional surgical evaluation of the axilla following preoperative\\ntherapy is required.     iii. If sentinel node biopsy performed before preoperative therapy was\\nnegative, no additional surgical evaluation of the axilla is required after preoperative therapy.\\niv. Sentinel node after preoperative therapy is allowed if no evidence of axillary node involvement\\nwas documented by ultrasonography at diagnosis. If sentinel node biopsy after preoperative therapy\\nis negative, no further additional surgical evaluation of the axilla is required. If sentinel node\\nbiopsy performed after preoperative therapy is positive, additional surgical evaluation of the\\naxilla is recommended. 4. Pathologic evidence of residual invasive carcinoma in the breast and/or\\naxillary lymph nodes on the surgical specimen obtained after preoperative therapy (ypT1micN0,\\nypT1micN0i+, ypT0N0i+ will be excluded). 5. Clinical stage at presentation: T1-4, N0-3, M0\\n(Exception: Patients with T1a/bN0 tumors at presentation will not be eligible). 6. No more than 10\\nweeks may elapse between the date of last treatment (surgery or post-surgery chemotherapy if\\nindicated) and the date of randomization. In case of positive margins after the first intervention\\nrequiring additional resection. 7. Availability of a formalin-fixed, paraffin-embedded block\\ncontaining tumor tissue or at least 7 unstained tumor slides (tumor sample from the diagnostic core-\\nbiopsy obtained before neoadjuvant chemotherapy). In case only 7 unstained slides from the bioptic\\nsample will be available, the investigator must ensure that the sample contains tumor tissue by\\nperforming an hematoxylin and eosin staining.  Exclusion criteria: Stratum A (Adjuvant patients) \\\\&\\nB (Post-neoadjuvant patients)  1. Stage IV breast cancer. 2. History of any prior (ipsi- and/or\\ncontralateral) invasive breast carcinoma diagnosed within 10 years. 3. Synchronous bilateral breast\\ncancer, unless both tumors confirmed as triple negative disease. 4. History of non-breast\\nmalignancies within the 5 years prior to study entry, except for the following: Carcinoma in situ\\n(CIS) of the cervix, CIS of the colon, Basal cell and squamous cell carcinomas of the skin. 5. Prior\\norgan transplantation, including allogeneic stem-cell transplantation. 6. Prior or concomitant\\ntreatment with any other investigational agents. 7. Prior therapy with any antibody / drug targeting\\nT-cell coregulatory proteins (immune-checkpoints) such as PD-1, PD-L1, or cytotoxic T-lymphocyte\\nantigen-4 (CTLA-4). 8. Concurrent anticancer treatment (for example, cytoreductive therapy, immune\\ntherapy, or cytokine therapy except for erythropoietin) 9. Major surgery for any reason, within 4\\nweeks of randomization and / or if the subject has not fully recovered from the surgery within 4\\nweeks of randomization. 10. Concomitant treatment with all herbal (alternative) remedies with\\nimmunostimulating properties (for example, mistletoe extract) or known to potentially interfere with\\nmajor organ function (for example, hypericin). 11. Subjects receiving immunosuppressive agents (such\\nas steroids) for any reason should be tapered off these drugs before initiation of the trial\\ntreatment (with the exception of subjects with adrenal insufficiency, who may continue\\ncorticosteroids at physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily). 12.\\nSignificant acute or chronic infections including, among others:      1. Known history of testing\\npositive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.\\n2. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface\\nantigen or HCV RNA if anti-HCV antibody screening test positive). 13. Active autoimmune disease that\\nmight deteriorate when receiving an immunostimulatory agent:      1. Subjects with diabetes type I,\\nvitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are\\neligible.     2. Subjects requiring hormone replacement with corticosteroids are eligible if the\\nsteroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or\\nequivalent prednisone per day.     3. Administration of steroids through a route known to result in\\na minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable. 14.\\nAdministration of steroids through a route known to result in a minimal systemic exposure (topical,\\nintranasal, intro-ocular, or inhalation) are acceptable. 15. Previous or ongoing administration of\\nsystemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is\\nanticipated that the administration of steroids will be completed in 14 days, or that the daily dose\\nafter 14 days will be ≤ 10 mg per day of equivalent prednisone. 16. Known severe hypersensitivity\\nreactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE v 4.03), any history of anaphylaxis, or\\nuncontrolled asthma (that is, 3 or more features of partially controlled asthma). 17. Clinically\\nsignificant (that is, active) cardiovascular disease: cerebral vascular accident /stroke (\\\\< 6\\nmonths prior to enrollment), myocardial infarction (\\\\< 6 months prior to enrollment), unstable\\nangina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious\\nuncontrolled cardiac arrhythmia requiring medication. 18. All other significant diseases (for\\nexample, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the\\nsubject's tolerance of trial treatment. 19. Any psychiatric condition that would prohibit the\\nunderstanding or rendering of informed consent. 20. Vaccination within 4 weeks of the first dose of\\navelumab and while on trial is prohibited except for administration of inactivated vaccines (for\\nexample, inactivated influenza vaccines). 21. Known alcohol or drug abuse. 22. Persisting toxicity\\nrelated to prior therapy of Grade \\\\> 1 NCI-CTCAE v 4.03 (except for grade 2 radiodermatitis and\\ngrade 2 neuropathy). 23. Current pregnancy and/or lactation. Refusal to adopt adequate contraception\\nmethods.  Stratum B (Postneoadjuvant patients)  1. No invasive residual disease in the breast and\\naxilla at pathological examination after neoadjuvant chemotherapy. ypT1micN0, ypT1micN0i+, ypT0N0i+\\nwill also be excluded.\",\n",
       "    'Interventions Description': 'MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration',\n",
       "    'NCT ID': 'NCT02926196',\n",
       "    'Official Title': 'Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova'}]],\n",
       " 'embeddings': None,\n",
       " 'documents': [[\"Clinical Trial Summary:\\n\\nNCT ID: NCT04502680\\nBrief Title: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple\\nNegative Breast Cancer Patients\\nBrief Summary: This clinical trial is a multicenter, randomized, open-label, phase-II study to\\nevaluate the efficacy and safety of maintenance treatment with eribulin mesylate\\nfollowing standard adjuvant chemotherapy in triple negative breast cancer\\npatients.\\nOfficial Title: A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy\\nand Safety of Maintenance Treatment With Eribulin Mesylate Following Standard\\nAdjuvant Chemotherapy in Triple Negative Breast Cancer Patients\\nConditions:\\n• Triple Negative Breast Cancer\\n\\nInterventions Description:\\n• Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * The patient volunteers and signs an informed consent form; * Age ≥18 years\\nold, female; * The patient was diagnosed as triple-negative breast cancer by histopathology (ER\\nnegative (IHC ER positive percentage \\\\<1%), PR negative (IHC PR positive percentage \\\\<1%), HER2\\nnegative (IHC-/+ or IHC++ but FISH/CISH- )), and there is no evidence of metastasis; * Patients\\nunderwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary\\nbreast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular\\ncarcinoma is not considered a positive margin. * For patients who have previously received\\nneoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the\\npostoperative efficacy evaluation did not reach pathological complete remission (non-PCR), that is,\\nthe primary breast and/or metastatic regional lymph nodes still have histological evidence of\\nmalignant tumors other than carcinoma in situ; * For patients who have not received neoadjuvant\\ntherapy for triple-negative breast cancer, ≥1 ipsilateral axillary lymph nodes have pathological\\ntumor involvement after surgery. Or the patient's postoperative lymph nodes are negative, but at\\nleast meet one of the following conditions:    1. Primary invasive tumor size\\\\> 2cm in pathology;\\n2. Ki-67 index of untreated breast tissue\\\\>30%;   3. The comprehensive score is at least 8 points\\n(Elston and Ellis 1991) according to the improved Bloom-Richardson grading system (also known as the\\nNottingham scale), which belongs to the 3rd level; * Physical condition ECOG PS: 0-1; * Previously\\nreceived adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines combined\\ntaxanes; * Time window between end of adjuvant chemotherapy and study randomization must be less\\nthan 8 weeks. In patients receiving adjuvant radiotherapy, time window allowed between last session\\nand randomisation is 4 weeks; * Laboratory tests meet the following criteria:    1. Bone marrow\\nfunction: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin\\n(HB)≥90g/L;   2. Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit\\nof normal (ULN) \\\\*1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN\\\\*2.5;\\n3. Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min\\n(calculated using the Cockcroft-Gault formula).  Exclusion Criteria:  * Patients with metastatic\\nbreast cancer (including contralateral axillary lymph nodes), inflammatory carcinomas; * Previous\\nbreast cancer history (except for ipsilateral DCIS that only received local treatment ≥5 years ago),\\nmalignant tumors of other histological origins (except for non-melanoma skin cancer or cervical\\ncarcinoma in situ) unless the patient's tumor had been completely alleviated and had not received\\ntreatment for at least 5 years before the enrollment date; * Major surgery within 4 weeks prior to\\nenrollment, or surgical wounds have not healed; * Embolization and bleeding occurred within 4 weeks\\nbefore enrollment; * Severe cardiovascular disease, including hypertension (BP≥160/95mmHg)\\nuncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6\\nmonths, congestive heart failure\\\\>NYHA II, severe heart rhythm Abnormalities and pericardial\\neffusions; * Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; *\\nSuffering from mental illness, poor compliance; * Researchers believe that it is not suitable for\\ninclusion.\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT05447702\\nBrief Title: Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in\\nParticipants With Triple Negative Breast Cancer (TNBC)\\nBrief Summary: The purpose of this study is to evaluate the efficacy and safety of camrelizumab\\nin combination with apatinib and chemotherapy as neoadjuvant therapy in\\nparticipants with triple negative breast cancer (TNBC).\\nOfficial Title: A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and\\nChemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)\\nConditions:\\n• Triple Negative Breast Cancer\\n\\nInterventions Description:\\n• Intravenous (IV) infusion • po. • IV infusion. • IV infusion. • IV infusion.\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 75 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * Newly diagnosed breast cancer. * 18-75 Years, female. * Early or locally\\nadvanced, histologically documented TNBC (absence of HER2, ER, and PR expression). * Tumor stage:\\nII-III. * ECOG Performance Status of 0-1. * life expectancy is not less than 3 months. * at least\\none measurable lesion according to RECIST 1.1. * Adequate hematologic and organ function. * Must be\\nwilling to use an adequate method of contraception for the course of the study.  Exclusion Criteria:\\n* Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer. * Inflammatory breast cancer. * Has\\nreceived prior any anti-tumor therapy within the past 12 months prior to signing informed consent,\\nincluding chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TAE. *\\nHas received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed\\ndeath-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory\\nT-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \\\\[CTLA-4\\\\], and/or anti-VEGFR\\nagent. * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for\\nadequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Major\\nsurgical procedure within 4 weeks prior to initiation of study treatment. * Has a history of\\nautoimmune disease. * Has a history of hypertension that not well controlled by antihypertensive\\ntreatment * Has a history of myocardial infarction, severe/unstable angina pectoris, NYHA Class 2 or\\nabove cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, or\\nsymptomatic congestive heart failure within the last 6 months. * Has a history of (non-infectious)\\npneumonitis, interstitial lung disease or uncontrollable systematicness diseases. * Administration\\nof a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation\\nof need for such a vaccine during the study. * Has a known history of Human Immunodeficiency Virus\\n(HIV). * Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis. * Severe infections\\nwithin 4 weeks prior to initiation of study treatment, including but not limited to hospitalization\\nfor complications of infection, bacteremia, or severe pneumonia. * Has active infection (CTCAE≥2)\\nneeded the treatment of antibiotic within 2 weeks prior to initiation of study treatment. * Has\\nevidence of active tuberculosis within 1 year prior to initiation of study treatment. * Prior\\nallogeneic stem cell or solid organ transplantation. * Peripheral neuropathy grade ≥2. * Has\\nclinically significant intestinal obstruction. * Arterial/venous thrombosis events that occurred\\nwithin 3 months before enrollment, such as cerebrovascular accidents, deep vein thrombosis, or\\npulmonary embolism. * Has hemoptysis symptoms within 2 months before enrollment and the maximum\\ndaily hemoptysis ≥ 2.5 ml. * Clinically significant bleeding symptoms or clear bleeding tendency\\noccurred within 3 months before enrollment. * Has known genetic or acquired bleeding or thrombotic\\ntendency. * Abnormal coagulation (INR\\\\>1.5 or APTT\\\\>1.5 x ULN) with bleeding tendency, receiving\\nthrombolysis or anticoagulation therapy, or requiring long-term antiplatelet therapy. * Has a known\\nhypersensitivity to the components of the study treatment or other hypersensitivity reactions to\\nchimeric or humanized antibodies or fusion proteins. * Female patients during pregnancy and\\nlactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are\\nunwilling to take effective contraceptive measures throughout the trial. * History of neurological\\nor psychiatric disorders, including epilepsy or dementia. * Any other situation evaluated by\\nresearchers.\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT05402722\\nBrief Title: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With\\nMetastatic Triple-Negative Breast Cancer\\nBrief Summary: To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in\\nPatients With Metastatic Triple-Negative Breast Cancer.\\nOfficial Title: A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients\\nWith Metastatic Triple-Negative Breast Cancer\\nConditions:\\n• TNBC - Triple-Negative Breast Cancer\\n\\nInterventions Description:\\n• Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle • Sintilimab\\nInjection，Intravenous infusion，200mg，3-week cycle\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 75 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. The patients sign the written informed consent. 2. Women aged 18-75. 3. The\\npathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［ER-\\nnegative(IHC\\\\<1%), PR-negative(IHC\\\\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］. Patients\\nwith at least one measuring lesion that was conformed to RECIST v1.1 standard. 4. PD-1/PD-L1positive\\nor TMB≥5. 5. Prior therapy (adjuvant/neoadjuvant/advanced) must have included an anthracycline\\nand/or a taxane in any combination or order and either in the early or metastatic disease setting\\nunless contraindicated for a given patient. 6. Eastern Cooperative Oncology Group (ECOG) performance\\nstatus of ≤ 1. 7. The results of patient's blood tests are as follows:     • Hb≥90g/L; •\\nPlt≥100\\\\^9/L; • Serum albumin ≥3g/dL;• Neutrophils≥1.5\\\\^9/L; TSH≤ normal upper limit (ULN);• ALT and\\nAST ≤1.5 ULN (liver metastases ≤3 ULN); • TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome\\nor liver metastasis subjects);• ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);• AKP≤ 2.5 ULN; •\\nRenal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or\\ncreatinine clearance ≥60mL/min 8. Female subjects of childbearing potential must have a negative\\nserum pregnancy test within 7 days before the first dose and must be willing to use very efficient\\nbarrier methods of contraception for the course of the study through 6 months after the last dose of\\nstudy treatment.  Exclusion Criteria:  1. The subjects had a central nervous system metastases with\\nclinical symptoms. 2. Subjects with treatment history of PD-1 / PD-L1 inhibitors; 3. Peripheral\\nneuropathy ≥ grade 2; Cardiac dysfunction, hyperthyroidism or hypothyroidism, type 1 diabetes,\\nactive hepatitis and tuberculosis; Autoimmune diseases requiring systemic treatment, and a history\\nof pneumonia (requiring corticosteroid treatment) or interstitial lung disease. 4. Pregnant or\\nlactating women. 5. Other clinical trials of drugs were used in the first four weeks before the\\nfirst dose. 6. The subjects had any history of autoimmune disease or any use of systemic\\nglucocorticoid or immunosuppressive medications. 7. Hereditary or acquired bleeding and thrombotic\\ntendencies (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.). 8.\\nCongenital or acquired immune deficiency (such as HIV infection); 9. Receive live vaccine within 4\\nweeks before or during the study period; 10. Patients who are allergic to or contraindicated to the\\nexperimental drugs. 11. Other malignant tumors in the past, except cervical cancer and non melanoma\\nskin cancer, which have survived for 5 years without disease. 12. Subjects with any other diseases\\nthat are unfit for the treatment.\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT05205200\\nBrief Title: Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)\\nBrief Summary: This study is a prospective, open-label, phase II clinical study for patients\\nwith HR+/HER2- advanced breast cancer.\\nOfficial Title: Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer\\nConditions:\\n• Breast Cancer\\n• Metastatic Cancer\\n\\nInterventions Description:\\n• PD-L1 antibody • CDK4/6 inhibitor • Albumin bound paclitaxel • Fulvestrant • aromatase inhibitor\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 75 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * Females ≥18 years and ≤ 75 years old; * Histologically confirmed HR + / HER2-\\ninvasive breast cancer (specific definition: immunohistochemical detection of ER\\\\> 10% tumor cell\\npositive is defined as ER positive, PR\\\\> 10% tumor cell positive is defined as PR positive, ER and /\\nor PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH\\ndetection, no amplification, defined as HER2 negative); * Subtype of similarity network fusion-2\\n(SNF-2) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan\\nUniversity Affiliated Cancer Hospital * Locally advanced breast cancer (incapable of radical local\\ntreatment) or recurrent metastatic breast cancer; * Measurable disease according to Response\\nEvaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic +\\nosteoblastic) bone lesions in the absence of measurable lesions; * Has adequate bone marrow\\nfunction: absolute neutrophil count \\\\> 1.5x10ˆ9 /L; platelet count \\\\> 75x10ˆ9 /L, hemoglobin \\\\>\\n9g/dL; * Patients had received no previous chemotherapy or targeted therapy for metastatic disease *\\nHas adequate liver function and kidney function: serum creatinine * ECOG score ≤ 2 and life\\nexpectancy ≥ 3 months; * Participants voluntarily joined the study, has signed informed consent\\nbefore any trial related activities are conducted, has good compliance and has agreed to follow-up.\\nExclusion Criteria:  * Treatment with chemotherapy, radiotherapy, immunotherapy or surgery\\n(outpatient clinic surgery excluded) for metastatic disease    * Symptomatic, untreated, or actively\\nprogressing CNS metastases(glucocorticoids or mannitol needed to control symptoms);   * Significant\\ncardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or\\nventricular arrhythmia in the last 6 months);   * is pregnant or breast feeding;   * Malignant\\ntumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in\\nsitu).   * History of autoimmune disease   * Positive test for human immunodeficiency virus   *\\nActive hepatitis B or hepatitis C   * Uncontrolled pleural effusion and ascites   * Thyroid\\ndysfunction.\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT05909332\\nBrief Title: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in\\nAdjuvant Therapy of TNBC-BLIS Patients.\\nBrief Summary: This is a randomized, open-label phase III clinical trial comparing antivascular\\ntherapy combined with standard chemotherapy and standard chemotherapy in\\nadjuvant therapy for patients with triple-negative breast cancer, basal-\\nlike/Immune suppressed subtype.\\nOfficial Title: A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy\\nCombined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant\\nTherapy for Patients With Triple-Negative Breast Cancer, Basal-like\\nImmunosuppressed Subtype.\\nConditions:\\n• Breast Cancer\\n• Triple Negative Breast Cancer\\n\\nInterventions Description:\\n• BP102 (anti VEGFR) • ddEC-P\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nMaximum Age: 70 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  * Women aged 18-70 years old; * Eastern Oncology Collaborative Group (ECOG)\\nphysical status score: 0 or 1; * Histological results recorded as TNBC (negative HER2, ER, and PgR\\nstatus) and BLIS subtype according to the classification of FUSCC; * Have stage IIA-IIIIC triple-\\nnegative breast cancer with non-metastatic surgically treated: pT1-3N1-3M0; * Adequate hematological\\nand end-organ function as defined by the following laboratory test results, which need to be\\ncompleted within 28 days prior to the first study treatment: absolute neutrophil count (ANC) ≥ 1500\\ncells/μL (no G-CSF support therapy within 2 weeks prior to day 1 of course 1); Platelet count ≥\\n75×109/L (no platelet transfusion within 2 weeks before day 1 of course 1); hemoglobin ≥ 9.0 g/dL\\n(no RBC transfusion within 2 weeks before day 1 of course 1); AST, ALT, and alkaline phosphatase ≤ 3\\n× upper limit of normal (ULN) serum total bilirubin ≤ 1.0 × ULN; serum creatinine ≤ 1ULN and with an\\nendogenous creatinine clearance rate of \\\\>50 ml/min (Cockcroft-Gault formula); * The surgical\\nincision had fully healed prior to the commencement of the study; * Female participants of\\nreproductive potential are required to use a medically accepted form of contraception during the\\ncourse of the study treatment and for at least three months following the last administration of the\\ninvestigational drug; * Sign the Informed Consent Form (ICF). The patient is judged by the\\ninvestigator to have the ability to comply with the provisions of the protocol.  Exclusion Criteria:\\n* Has received neoadjuvant therapy (including chemotherapy, targeted therapy, and radiotherapy) *\\nHas bilateral breast cancer; * Has a previous history of additional malignancy, with the exception\\nof adequately treated basal cell carcinoma and cervical carcinoma in situ. * Has metastatic (Stage\\n4) breast cancer; * Has any \\\\>T4 lesion (UICC1987) (with skin involvement, mass adhesion and\\nfixation, and inflammatory breast cancer); * Has severe organ dysfunction (cardiopulmonary liver and\\nkidney) insufficiency, left ventricular ejection fraction (LVEF) \\\\< 50% (a cardiac ultrasound);\\nsevere cardio cerebral vascular disease within the 6 months previous to randomization (such as\\nunstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\\\\>150/90mmgh,\\nmyocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control;\\npatients with severe hypertension; * Is pregnant, breastfeeding women, or women of childbearing age\\nwho cannot practice effective contraceptives; * Patients participating in other clinical trials at\\nthe same time; * Has known allergy to taxane and excipients. * Has severe or uncontrolled infection;\\n* Has a history of psychotropic substance abuse and was unable to abandon drug habits or those with\\na history of mental disorders; * the researchers judged patients to be unsuitable for the study.\",\n",
       "   'Clinical Trial Summary:\\n\\nNCT ID: NCT04567420\\nBrief Title: DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III,\\nHormone Receptor Positive, HER2 Negative Breast Cancer\\nBrief Summary: A randomized, Phase II trial of circulating tumor DNA-guided second line\\nAdjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor\\npositive, HER-2 negative breast cancer (DARE)\\nOfficial Title: A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant\\nTherapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2\\nNegative Breast Cancer\\nConditions:\\n• Breast Cancer\\n\\nInterventions Description:\\n• 4 week cycles • 4 week cycles • Standard of Care\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nStandard Ages: [\\'CHILD\\', \\'ADULT\\', \\'OLDER_ADULT\\']\\nInclusion Criteria:  - 4.1.1. Stage II or III, HER2 negative, ER positive invasive breast cancer in\\nmale or female patients. For this study, ER positivity is defined as equal to or greater than 10% ER\\npositivity by immunohistochemistry, regardless of progesterone receptor (PR) status. Patients with\\nPR positive but ER negative cancer are not eligible. HER2 negative status is defined as per the\\nASCO/CAP 2018 practice guidelines.  (i) if patients have synchronous bilateral ER+ breast cancer\\ntissue from both sites should be submitted to Natera to perform ctDNA testing.  (ii) patients with\\nmultifocal/multicentric tumors are eligible and the largest focus of cancer should be submitted for\\ntesting. All tumors must meet pathological criteria for HER2-and ER+ status.  (iii) For. patients\\nwho received neoadjuvant therapy and have discordant ER and HER2 results between the diagnostic\\nbiopsy (pre-treatment) and surgical pathology (post neoadjuvant therapy), the ER+ and HER2- status\\nof the post-treatment specimen determine eligibility.  4.1.2. Currently taking an aromatase\\ninhibitor, or tamoxifen, as adjuvant endocrine therapy and have completed at least 6 months (i.e. 24\\nweeks), but no more than 7 years with 3 more years planned, of endocrine therapy. Patients may\\nregister for the screening phase of the study within the first 6 months of adjuvant endocrine\\ntherapy but the first ctDNA testing must occur at, or after, 6 months of endocrine therapy.  (i)\\nAdjuvant bisphosphonate therapy is allowed. (ii) LHRH analogues are required for premenopausal\\npatients randomized to receive fulvestrant.  4.1.3. Clinical and pathological high risk for\\nrecurrence defined as any one of the following: (i) At least a 15% predicted risk of death within 10\\nyears using ePREDICT V2.1 (https://breast.predict.nhs.uk/tool), or (ii) At least 15% or greater risk\\nof distant metastasis within 10 years using RSPC,\\n(https://tools.genomichealth.com/Tools/RSPCTool.aspx), or (iii) At least 15% or greater risk of\\ndistant metastasis within 10 years CTS5 (https://www.cts5-calculator.com) for patients who have\\ncompleted a minimum of 4 years of adjuvant endocrine therapy, or (iv) Tumor size \\\\> 5 cm, regardless\\nof lymph node status, or (v) 1-3 involved axillary lymph nodes and at least one of the following;  *\\nTumor size \\\\> 3 cm, * High histological grade (e.g. grade 3). * High genomic risk defined as\\nOncotype Dx Recurrence Score \\\\>26, EndoPredict score \\\\>4, Prosigna risk of recurrence score ≥ 60, or\\nMammaprint high risk.  (vi) Patients who have received pre-operative (neoadjuvant) chemotherapy must\\nhave either:  * greater than or equal to 3 cm invasive residual cancer regardless of nodal status\\nAND grade 3 disease or RS\\\\>26/MammPrint High/Prosigna high/Endopredict high status, or * greater\\nthan or equal to 1 cm invasive residual cancer (ypT1c) and at least 1 positive lymph node (ypN+) AND\\ngrade 3 disease, or RS\\\\>26, or MammPrint High, or Endopredict high or Prosigna high status.  4.1.4.\\nPatients must have FFPE tissue from the primary tumor available for submission to Natera to perform\\nctDNA assay (see Appendix B for tissue submission instructions).  4.1.5. Signed and dated informed\\nconsent, including willingness to be randomized to standard of care versus fulvestrant +\\npalbociclib.  4.2 Inclusion and exclusion criteria for treatment randomization  Inclusion criteria\\nfor randomization  4.2.1. ctDNA positivity by the Signatera assay, defined as 2 of the 16 cancer\\nspecific markers positive in plasma.  4.2.2. Patients with positive Signatera results obtained in\\nthe context of commercial testing, outside of the screening phase of this trial, are also eligible\\nfor randomization if they meet other eligibility criteria.  4.2.3. No evidence of metastatic disease\\non CT scan of the chest, abdomen and pelvis.  * If imaging, after review with a radiologist, is low\\nprobability for metastatic disease, patients may proceed to randomization. * Patients with\\nsuspicious but inconclusive imaging results should undergo a diagnostic biopsy, if biopsy is\\nnegative patients are eligible for randomization. * Patients with positive imaging that is\\nconclusive of metastatic disease, or with biopsy proven metastatic disease, are not eligible for\\nrandomization.  4.2.4. Pre-menopausal women and male patients must be willing to use an adequate\\nmethod of contraception for the duration of trial treatment and for 4 additional weeks after\\ncompletion of treatment in the control arm, and for 2 years after the last dose of fulvestrant, if\\nrandomized into the experimental arm.  Post-menopausal status is defined as:  * Documented bilateral\\noophorectomy. * Age ≥ 60 years. * Age \\\\< 60 years and amenorrhoeic for ≥ 12 consecutive months and\\nFSH and estradiol levels in the post-menopausal range according to the institutional reference range\\nfor post-menopausal.  Adequate contraception is defined as ONE highly effective form (i.e.\\nabstinence, surgical sterilization through bilateral tubal ligation, vasectomy), or TWO effective\\nforms (e.g. non-hormonal IUD and condom / occlusive cap with spermicidal foam / gel / film / cream /\\nsuppository).  - Abstinence is to be interpreted as \"true abstinence\" for heterosexual intercourse\\nand therefore, \"periodic abstinence\" (e.g. calendar, symptothermal, post-ovulation methods) and\\nwithdrawal (coitus interruptus) are not considered highly effective.  Exclusion Criteria  4.1.5.\\nPrior or current treatment with fulvestrant, or current treatment with a CDK4/6 inhibitor, or\\ntreatment in the prior 12 months, or participants in the PENELOPE and PALLAS clinical trials.\\n4.1.6. Patients cannot start participation in another therapeutic clinical trial for breast cancer\\nafter enrollment in this trial.  4.1.7. Patients with current or past invasive cancer, other than\\nbreast cancer are not eligible, except:  * Adequately treated basal or squamous cell carcinoma of\\nthe skin are eligible. * Cancer survivors of previously diagnosed invasive cancer, who were treated\\nwith a curative intent, have no evidence of disease recurrence for 5 years or more, and are\\nconsidered low risk for future recurrence by the treating physician are also eligible.  4.1.8.\\nPatients with a second HER2 positive or triple negative synchronous breast cancer are not eligible.\\nExclusion criteria for randomization  4.2.5. Patients with known contraindications to receive\\nfulvestrant and palbociclib or those who are unable to tolerate these drugs are not eligible.  *\\nAbsolute neutrophil count less than \\\\<1000/mm3;  4.2.6. Any concurrent severe and uncontrolled\\nmedical condition that would, in the Investigator\\' opinion cause unacceptable safety risks or\\ncompromise compliance with the protocol including but not limited to:  * Impairment of\\ngastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral\\nmedication (e.g. Crohn\\'s disease, ulcerative diseases, uncontrolled chronic nausea, vomiting,\\ndiarrhea, malabsorption syndrome, or small bowel resection). * History of pneumonitis, interstitial\\nlung disease or pulmonary fibrosis. * Known history of Human Immunodeficiency Virus (HIV) (testing\\nis not mandatory). * Known active Hepatitis B or Hepatitis C (testing is not mandatory). * Females\\nwho are pregnant or breastfeeding. * History of bleeding diathesis (i.e. disseminated intravascular\\ncoagulation, clotting factor deficiency) that preclude the IM injections of fulvestrant or LHRH\\nagonist as applicable.  4.2.7 Patients taking any CYPC3A4 strong inducers and inhibitors, that\\ncannot be changed.',\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT03077776\\nBrief Title: Tracking Triple-negative Breast Cancer Evolution Through Therapy\\nBrief Summary: A prospective multicentre study which aims to examine the relationship between\\nintratumour heterogeneity (ITH) and pathological response to neoadjuvant\\nchemotherapy in patients with histological confirmation of triple-negative\\nbreast cancer (TNBC) who are eligible for neoadjuvant chemotherapy.\\nOfficial Title: Tracking Triple-negative Breast Cancer Evolution Through Therapy\\nConditions:\\n• Triple-Negative Breast Neoplasm\\n\\nInterventions Description:\\n• Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy •\\n\\\\[Optional\\\\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy •\\nBiopsy of metastatic site to be performed at the time of relapse\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. Age 18-years or older 2. Patients with histological confirmation of invasive\\nbreast cancer with known receptor status suitable for neoadjuvant chemotherapy as assessed by the\\nlocal investigator 3. Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by\\n≤1% of positive staining on immunohistochemistry 4. Human epidermal growth factor receptor 2\\n(HER2)-negative as defined by American Society of Clinical Oncology / College of American\\nPathologists guidelines 5. T1c-4 tumours (including inflammatory cancers), with any nodal status non\\ncandidate for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided\\nthat all sites are HER2-negative and at least one site is ER- and PR-negative. 6. Provision of\\nsigned and dated, written informed consent prior to any study specific procedures, sampling and\\nanalyses 7. Patient with social insurance coverage  Exclusion Criteria:  1. Confirmed metastatic\\ndisease at initial presentation 2. Any contraindication to the biopsy procedure 3. Previous or\\ncurrent malignancies of other origin within the last 5 years, with the exception of in situ\\ncarcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin 4.\\nAny condition which in the Investigator's opinion makes it undesirable for the subject to\\nparticipate in the trial or which would jeopardize compliance with the protocol 5. Individuals\\ndeprived of liberty or placed under the authority of a tutor\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT05749588\\nBrief Title: FUSCC Refractory TNBC Platform Study (FUTURE2.0)\\nBrief Summary: This is a Phase II, open-label, Single-center platform study research based on\\nmolecular subtypes to explore precision therapy in refractory triple-negative\\nbreast cancer.\\nOfficial Title: Precision Platform Study of Refractory Triple-negative Breast Cancer Based on\\nMolecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）\\nConditions:\\n• Triple-negative Breast Cancer\\n\\nInterventions Description:\\n• A1: an anti-HER2 antibody-drug conjugate (ADC) • A2: SHR-A1811: an anti-HER2 antibody-drug\\nconjugate (ADC)  Camrelizumab: an anti-programmed death-1 (PD-1) antibody • B1: an Trophoblast cell-\\nsurface antigen 2 (TROP2) ADC • B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC\\nCamrelizumab: an anti-programmed death-1 (PD-1) antibody • C1: an anti-HER2 antibody-drug conjugate\\n(ADC) • C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)  BP102: a humanized recombinant\\nmonoclonal IgG1 antibody (biosimilar to bevacizumab) • D1: an Trophoblast cell-surface antigen 2\\n(TROP2) ADC • D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC  BP102: a humanized\\nrecombinant monoclonal IgG1 antibody (biosimilar to bevacizumab) • E1: an anti-HER2 antibody-drug\\nconjugate (ADC) • F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC • G1: an anti-HER2 antibody-\\ndrug conjugate (ADC) • H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: FEMALE\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. Female aged ≥18 years; 2. TNBC invasive breast cancer confirmed by histology\\n(specific definition: ER \\\\<1% positive tumor cells by immunohistochemistry is defined as ER\\nnegative, PR \\\\<1% positive tumor cells is defined as PR negative, HER2 0-1+ or HER2 ++ but negative\\nby FISH without amplification was defined as HER2 negative); Locally advanced breast cancer (unable\\nto undergo radical local treatment) or recurrent metastatic breast cancer; 3. Progression after at\\nleast one prior therapeutic regimens for advanced/metastatic TNBC 4. At least one measurable lesion\\naccording to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has\\nnot received radiotherapy); 5. The functions of the main organs are basically normal and meet the\\nfollowing conditions:     i. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood\\ntransfusion within 14 days); The ANC acuity 1.5 x 109 / L; PLT acuity 75 x 109 / L;     ii.\\nBiochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value);\\nALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN,\\nendogenous creatinine clearance \\\\> 50 ml/min (Cockcroft-Gault formula); 6. They have not received\\nradiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study,\\nand have recovered from the acute toxicity of previous treatment (if surgery was performed, the\\nwound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity; 7. ECOG\\nscore ≤1, and life expectancy ≥3 months; 8. Fertile female subjects were required to use a medically\\napproved contraceptive method during the study treatment period and for at least 3 months after the\\nlast use of the study drug; 9. Subjects volunteered to join the study, signed informed consent, had\\ngood compliance, and cooperated with follow-up.  Exclusion Criteria:  1. Radiotherapy (except for\\npalliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment,\\nexcept bisphosphonate (which can be used for bone metastasis); 2. Uncontrolled central nervous\\nsystem metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or\\nmannitol); 3. A history of clinically important or uncontrolled heart disease, including congestive\\nheart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6\\nmonths; 4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The\\nexception to this is hair loss or something the researchers don't think should be ruled out. Such\\ncases should be clearly documented in the investigator's notes; 5. Underwent major surgery (except\\nminor outpatient procedures, such as placement of vascular access) within 3 weeks of the first\\ncourse of trial treatment; 6. Pregnant or lactating patients; 7. Malignancy (except basal cell\\ncarcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5\\nyears.\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT05722795\\nBrief Title: Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast\\nCancer (I-CONIC)\\nBrief Summary: This is a single centre Window-of-Opportunity trial investigating the efficacy\\nand feasibility of short term imatinib in patients with newly diagnosed triple\\nnegative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any\\nstatus in the axilla when neoadjuvant treatment not is considered as an option.\\nThe primary aim is to determine the proportion of patients that converts to\\nestrogen receptor (ER) positive breast cancer in the removed breast cancer\\ntissue at surgery.\\nOfficial Title: Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast\\nCancer\\nConditions:\\n• Breast Cancer\\n• Triple Negative Breast Cancer\\n\\nInterventions Description:\\n• One tablet daily 10 days before surgery.\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria:  1. Histological confirmed invasive primary triple negative breast cancer≥15 mm)\\nwith any node status. 2. Age ≥18 years     Triple Negative subtype is defined below:    1. Hormone\\nreceptor status: the invasive tumour shall be ER- and progesterone receptor (PR) -negative\\n\\\\[staining present in \\\\<10% by immunohistochemistry (IHC)\\\\].    2. HER2 status: the invasive tumour\\nshall be Human Epidermal growth factor Receptor (HER) 2-negative by the American Society of Clinical\\nOncology (ASCO) / College of American Pathologists (CAP) guidelines 3. No previous systemic\\ntreatment for TNBC 4. No concurrent anti-cancer treatment. Treatment with Bisphosphonates may\\ncontinue. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 6. Normal organ\\nfunction as defined below:     1. absolute white blood cell count ≥1.5 x 109/L    2. platelets ≥100\\nx 109/L    3. haemoglobin ≥90g/dL    4. total bilirubin ≤1.5 x institutional upper normal limit\\n(UNL)/dL (≤ 3 x UNL for patients with Gilbert´s syndrome)    5. ASAT, ALAT, GGT and alkaline\\nphosphatase levels \\\\< 1.5 × institutional UNL.    6. albumin \\\\>2.5mg/dL    7. Creatinine \\\\< 110\\nμmol/L    8. T3, T4 and TSH (only patients with previous thyroid dysfunction) 7. Patients of\\nchildbearing potential must have a negative serum or urine pregnancy test within 8 days prior to\\nstart of imatinib treatment..     Female patients of childbearing potential must agree to\\nusecontraceptive methods with a failure rate below 1% per year during the study treatment and at\\nleast 90 days after the last dose of imatinib. 8. Patients must be able to take (swallow) an oral\\nmedication. 9. Patients must be capable to understand and comply with the protocol and has signed\\nthe informed consent.  Exclusion Criteria:  1. Patients suitable for neoadjuvant treatment. 2.\\nConcomitant treatment for breast cancer within 14 days before registration. 3. Unable to adhere to\\nthe study procedures. 4. Evidence of any other medical conditions (such as psychiatric illness,\\ninfectious diseases, neurological conditions, physical examination or laboratory findings) that may\\ninterfere with the planned treatment or affect patient compliance. 5. Pregnancy and breast-feeding.\\n6. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).\\n7. Known human immunodeficiency virus (HIV) positivity. 8. Known active Hepatitis B or Hepatitis C\",\n",
       "   \"Clinical Trial Summary:\\n\\nNCT ID: NCT02926196\\nBrief Title: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the\\nAnti-PD-l1 Antibody Avelumab\\nBrief Summary: Phase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or\\npost-neoadjuvant treatment for high-risk triple negative breast cancer patients.\\nThe overall protocol-defined patient population will include the following two\\nstrata of patients:  * Stratum A - Patients who have completed treatment with\\ncurative intent including surgery of the primary tumor followed by adjuvant\\nchemotherapy . * Stratum B - Patients who have completed treatment with curative\\nintent including neoadjuvant chemotherapy followed by surgery of the primary\\ntumor and (if indicated) further adjuvant chemotherapy.\\nOfficial Title: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the\\nAnti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor:\\nDipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche,\\nUniversità di Padova\\nConditions:\\n• Triple Negative Breast Neoplasms\\n\\nInterventions Description:\\n• MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration\\n\\nEligibility Criteria:\\nHealthy Volunteers: False\\nSex: ALL\\nMinimum Age: 18 Years\\nStandard Ages: ['ADULT', 'OLDER_ADULT']\\nInclusion Criteria Stratum A (Adjuvant patients) \\\\& B (Post-neoadjuvant patients)  1. Male or female\\nsubjects aged \\\\> 18 years 2. Signed written informed consent before any trial-related procedure is\\nundertaken that is not part of the standard patient management 3. Eastern Cooperative Oncology Group\\n(ECOG) performance status 0 or 1 4. Patients must have completed treatment with curative intent\\nincluding: surgery and adjuvant chemotherapy. 5. Patients must have completed adjuvant chemotherapy\\nincluding at least 3 courses of an anthracycline agent and 3 courses of a taxane agent. Patients who\\nreceived dose-dense regimens and those who received carboplatin as part of the adjuvant treatment\\nare eligible. 6. No more than 10 weeks may elapse between the completion of last adjuvant treatment\\n(adjuvant chemotherapy or surgery) and randomization.  8. Normal organ and marrow function  1. White\\nblood count (WBC) greater than or equal to 2.5 x109/L 2. Absolute neutrophil count (ANC) greater\\nthan or equal to 1.5 x109/L 3. Absolute lymphocyte count greater or equal to 0.5 x109/L 4. Platelet\\ncount greater than or equal to 100 x109/L 5. Hemoglobin greater than or equal to 9 g/dL 6. Serum\\ncreatinine less or equal to 1.5 x the upper limit of laboratory normal range (ULN) 7. Adequate\\nhepatic function defined by a total bilirubin level less or equal to 1.5 x ULN range and AST and ALT\\nlevels less or equal than 2.5 x ULN for all subjects. For patients with known Gilbert's syndrome,\\ntotal bilirubin levels less or equal than 2 x ULN range (with direct bilirubin less than ULN) will\\nbe accepted.     9. Highly effective contraception (i.e. methods with a failure rate of less than 1\\n% per year) for both male and female subjects if the risk of conception exists (Note: The effects of\\nthe trial treatment on the developing human fetus are unknown; thus, women of childbearing potential\\nand men must agree to use highly effective contraception, defined in Appendix A or as stipulated in\\nnational or local guidelines. Highly effective contraception must be used 28 days prior to first\\ntrial treatment administration, for the duration of trial treatment, and at least for 60 days after\\nstopping trial treatment. Should a woman become pregnant or suspect she is pregnant while she or her\\npartner is participating in this trial, the treating physician should be informed immediately).\\n10. Ability to understand and willingness to sign a written informed consent.  Inclusion Criteria\\nStratum A (Adjuvant patients)  1. Non-metastatic, histologically confirmed primary invasive breast\\ncarcinoma 2. Triple negative breast cancer: hormone receptor negative (ER \\\\< 10% and PgR \\\\< 10%) and\\nHER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory. In case\\nof discordance between pre-operative core-biopsy and the surgical sample, the receptor assessment\\nperformed on the surgical sample has to be considered for inclusion criteria evaluation. 3.\\nAvailability of a formalin-fixed, paraffin-embedded block containing tumor tissue or at least 7\\nunstained tumor slides. 4. Adequately excised: patients must have undergone either breast-conserving\\nsurgery or mastectomy/nipple- or skin-sparing mastectomy. The margins of the resected specimen\\nshould be free of invasive tumor and ductal carcinoma in situ (no ink on tumor). In the case of\\nbreast-conserving surgery patients with margins positive for lobular carcinoma in situ (LCIS) are\\neligible without additional resection. For patients who undergo mastectomy, patients with a\\nmicroscopic positive deep margin are eligible, provided they will receive radiotherapy on chest\\nwall. 5. Patients must have had axillary lymph node dissection for evaluation of pathologic nodal\\nstatus. Only patients in one of the following stage categories will be eligible:     * if 4 or more\\nmetastatic lymph nodes, any pT    * if 1 to 3 metastatic lymph nodes, pT \\\\>2 cm    * if no\\nmetastatic lymph nodes, pT \\\\>5 cm  Inclusion criteria:  Stratum B (Post-neoadjuvant patients)  1.\\nNon-metastatic histologically confirmed invasive breast carcinoma. 2. Triple negative breast cancer:\\nhormone receptor negative (ER \\\\< 10% and PgR \\\\< 10%) and HER2 negative (IHC 0/1+ or ISH non-\\namplified), as defined by the local pathology laboratory. In case of discordance between the pre-\\ntreatment diagnostic core-biopsy and the surgical sample, the receptor assessment performed on the\\nsurgical sample has to be considered for inclusion criteria evaluation. 3. Adequately excised:\\npatients should have undergone adequate tumor excision after preoperative chemotherapy, which means\\nsurgical removal of all clinically evident disease in the breast and lymph nodes.     1. Breast\\nsurgery: patients must have undergone either breast-conserving surgery or mastectomy/nipple- or\\nskin-sparing mastectomy. The margins of the resected specimen should be free of invasive tumor and\\nductal carcinoma in situ (no ink on tumor). In the case of breast-conserving surgery patients with\\nmargins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection. For\\npatients who undergo mastectomy, patients with a microscopic positive deep margin are eligible,\\nprovided they will receive radiotherapy on chest wall.    2. Lymph node surgery:     i. Axillary\\ndissection without sentinel node evaluation is permitted after preoperative therapy.     ii. In case\\nof positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed\\nprior to preoperative therapy, additional surgical evaluation of the axilla following preoperative\\ntherapy is required.     iii. If sentinel node biopsy performed before preoperative therapy was\\nnegative, no additional surgical evaluation of the axilla is required after preoperative therapy.\\niv. Sentinel node after preoperative therapy is allowed if no evidence of axillary node involvement\\nwas documented by ultrasonography at diagnosis. If sentinel node biopsy after preoperative therapy\\nis negative, no further additional surgical evaluation of the axilla is required. If sentinel node\\nbiopsy performed after preoperative therapy is positive, additional surgical evaluation of the\\naxilla is recommended. 4. Pathologic evidence of residual invasive carcinoma in the breast and/or\\naxillary lymph nodes on the surgical specimen obtained after preoperative therapy (ypT1micN0,\\nypT1micN0i+, ypT0N0i+ will be excluded). 5. Clinical stage at presentation: T1-4, N0-3, M0\\n(Exception: Patients with T1a/bN0 tumors at presentation will not be eligible). 6. No more than 10\\nweeks may elapse between the date of last treatment (surgery or post-surgery chemotherapy if\\nindicated) and the date of randomization. In case of positive margins after the first intervention\\nrequiring additional resection. 7. Availability of a formalin-fixed, paraffin-embedded block\\ncontaining tumor tissue or at least 7 unstained tumor slides (tumor sample from the diagnostic core-\\nbiopsy obtained before neoadjuvant chemotherapy). In case only 7 unstained slides from the bioptic\\nsample will be available, the investigator must ensure that the sample contains tumor tissue by\\nperforming an hematoxylin and eosin staining.  Exclusion criteria: Stratum A (Adjuvant patients) \\\\&\\nB (Post-neoadjuvant patients)  1. Stage IV breast cancer. 2. History of any prior (ipsi- and/or\\ncontralateral) invasive breast carcinoma diagnosed within 10 years. 3. Synchronous bilateral breast\\ncancer, unless both tumors confirmed as triple negative disease. 4. History of non-breast\\nmalignancies within the 5 years prior to study entry, except for the following: Carcinoma in situ\\n(CIS) of the cervix, CIS of the colon, Basal cell and squamous cell carcinomas of the skin. 5. Prior\\norgan transplantation, including allogeneic stem-cell transplantation. 6. Prior or concomitant\\ntreatment with any other investigational agents. 7. Prior therapy with any antibody / drug targeting\\nT-cell coregulatory proteins (immune-checkpoints) such as PD-1, PD-L1, or cytotoxic T-lymphocyte\\nantigen-4 (CTLA-4). 8. Concurrent anticancer treatment (for example, cytoreductive therapy, immune\\ntherapy, or cytokine therapy except for erythropoietin) 9. Major surgery for any reason, within 4\\nweeks of randomization and / or if the subject has not fully recovered from the surgery within 4\\nweeks of randomization. 10. Concomitant treatment with all herbal (alternative) remedies with\\nimmunostimulating properties (for example, mistletoe extract) or known to potentially interfere with\\nmajor organ function (for example, hypericin). 11. Subjects receiving immunosuppressive agents (such\\nas steroids) for any reason should be tapered off these drugs before initiation of the trial\\ntreatment (with the exception of subjects with adrenal insufficiency, who may continue\\ncorticosteroids at physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily). 12.\\nSignificant acute or chronic infections including, among others:      1. Known history of testing\\npositive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.\\n2. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface\\nantigen or HCV RNA if anti-HCV antibody screening test positive). 13. Active autoimmune disease that\\nmight deteriorate when receiving an immunostimulatory agent:      1. Subjects with diabetes type I,\\nvitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are\\neligible.     2. Subjects requiring hormone replacement with corticosteroids are eligible if the\\nsteroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or\\nequivalent prednisone per day.     3. Administration of steroids through a route known to result in\\na minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable. 14.\\nAdministration of steroids through a route known to result in a minimal systemic exposure (topical,\\nintranasal, intro-ocular, or inhalation) are acceptable. 15. Previous or ongoing administration of\\nsystemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is\\nanticipated that the administration of steroids will be completed in 14 days, or that the daily dose\\nafter 14 days will be ≤ 10 mg per day of equivalent prednisone. 16. Known severe hypersensitivity\\nreactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE v 4.03), any history of anaphylaxis, or\\nuncontrolled asthma (that is, 3 or more features of partially controlled asthma). 17. Clinically\\nsignificant (that is, active) cardiovascular disease: cerebral vascular accident /stroke (\\\\< 6\\nmonths prior to enrollment), myocardial infarction (\\\\< 6 months prior to enrollment), unstable\\nangina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious\\nuncontrolled cardiac arrhythmia requiring medication. 18. All other significant diseases (for\\nexample, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the\\nsubject's tolerance of trial treatment. 19. Any psychiatric condition that would prohibit the\\nunderstanding or rendering of informed consent. 20. Vaccination within 4 weeks of the first dose of\\navelumab and while on trial is prohibited except for administration of inactivated vaccines (for\\nexample, inactivated influenza vaccines). 21. Known alcohol or drug abuse. 22. Persisting toxicity\\nrelated to prior therapy of Grade \\\\> 1 NCI-CTCAE v 4.03 (except for grade 2 radiodermatitis and\\ngrade 2 neuropathy). 23. Current pregnancy and/or lactation. Refusal to adopt adequate contraception\\nmethods.  Stratum B (Postneoadjuvant patients)  1. No invasive residual disease in the breast and\\naxilla at pathological examination after neoadjuvant chemotherapy. ypT1micN0, ypT1micN0i+, ypT0N0i+\\nwill also be excluded.\"]]}"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "print(collection.query(\n",
    "    query_texts=[\n",
    "\"\"\"                            \n",
    "The patient is a 60-year-old pre-menopausal woman presenting with a history of grade-3 locally advanced, triple-negative breast cancer on her left side. Despite neoadjuvant chemotherapy and subsequent mastectomy, the cancer has recurred, indicating progressive disease. Her current ECOG score is 1, signifying she is active but limited in strenuous physical activity. \n",
    "\n",
    "The breast tumor is triple-negative as denoted by ER negativity (IHC<1%), PR negativity (IHC<1%), and HER2 negativity (IHC-/+ or IHC++ but FISH/CISH negative). The invasive tumor measures 4 cm with one objectively measurable lesion via RECIST 1.1 standard. She has no prior treatment experience with PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy. \n",
    "\n",
    "Recent blood reports show Hemoglobin of 95 g/L, Neutrophil count of 2.5×109/L, Platelet count of 120×109/L. Biochemical tests results reveal Total Bilirubin of 1.2×ULN, Alanine aminotransferase and Aspartate aminotransferase both at 1.5×ULN, and Serum creatinine of 1.3 ULN with a creatinine clearance of 70mL/min.\n",
    "\n",
    "She has a history of smoking but no family history of breast cancer. The patient reports no known autoimmune diseases, serious infections, interstitial lung disease, or non-infectious pneumonia, or other harmful medical conditions. There have been no major surgical treatments or open biopsies conducted within the past 4 weeks.                 \n",
    "\"\"\"],\n",
    "    n_results=10,\n",
    "    # where={\"metadata_field\": \"is_equal_to_this\"},\n",
    "    # This filters the results THEN ranks them with the embeddings.\n",
    "    # where_document={\"$contains\":\"search_string\"}\n",
    ")['documents'][0][0])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
